[The effect of flupirtine on respiratory drive in healthy probands and patients with various lung diseases].
We investigated the effect of a novel analgesic compound, flupirtine on the respiratory center in 8 healthy controls and patients with lung emphysema (n = 6), bronchial asthma (n = 7) and lung fibrosis (n = 5). All patients received a in a double blind, randomized fashion on three separate study days 100 mg and 200 mg flupirtine and placebo, respectively. Respiratory drive was estimated from measurements of CO2-rebreathing curves and mouth occlusion pressure at rest and during CO2-rebreathing performed before, 1.5 and 3 hours after medication. We were unable to detect any significant depression of respiratory drive neither in the controls nor in the patients and therefore suggest that flupirtine is a safe analgetic compound even in patients with severe obstructive and restrictive lung function impairment.
Magnussen
H
H
Zentrum für Pneumologie und Thoraxchirurgie, Krankenhaus, Grosshansdorf.
Scheidt-Mackes
M
M
D000403:Airway Resistance / Q000187:drug effects / Q000502:physiology; D000631:Aminopyridines / Q000494:pharmacology*; D000700:Analgesics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology*; D012123:Pulmonary Ventilation / Q000187:drug effects* / Q000502:physiology; D012125:Respiratory Center / Q000187:drug effects* / Q000503:physiopathology
D000631:Aminopyridines; D000700:Analgesics; C034161:flupirtine
Der Einfluss von Flupirtin auf den Atemantrieb gesunder Probanden und Patienten mit verschiedenen Lungenerkrankungen.